Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Design, synthesis, and in silico studies of new quinazolinones tagged thiophene, thienopyrimidine, and thienopyridine scaffolds as antiproliferative agents with potential p38α MAPK kinase inhibitory effects
Aisha A. Alsfouka,
Ismail M. M. Othmanb,
Manal M. Anwar*c,
Asmaa Saleha and
Eman S. Nossier*de
aDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P. O. Box 84428, Riyadh 11671, Saudi Arabia
bDepartment of Chemistry, Faculty of Science, Al-Azhar University, Assiut 71524, Egypt
cDepartment of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El-Bohouth Street, Dokki, P. O. Box 12622, Cairo, Egypt. E-mail: manal.hasan52@live.com
dPharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, 11754, Egypt. E-mail: dr.emannossier@gmail.com; dremannossier@azhar.edu.eg
eThe National Committee of Drugs, Academy of Scientific Research and Technology, Cairo, 11516, Egypt
First published on 27th January 2025
Abstract
Correction for ‘Design, synthesis, and in silico studies of new quinazolinones tagged thiophene, thienopyrimidine, and thienopyridine scaffolds as antiproliferative agents with potential p38α MAPK kinase inhibitory effects’ by Aisha A. Alsfouk et al., RSC Adv., 2025, 15, 1407–1424, https://doi.org/10.1039/D4RA06744D.
The authors regret that an incorrect grant number was shown in the acknowledgements section of the published article. The corrected section should read:
This research was funded by Princess Nourah bint Abdulrahman University researchers supporting project number (PNURSP2025R116), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2025 |